• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ViaCyte appoints Altman to board of directors

ViaCyte appoints Altman to board of directors

November 1, 2012
CenterWatch Staff

ViaCyte, a San Diego-based regenerative medicine company developing transformative cell therapy for diabetes, as appointed Steve R. Altman to its board of directors.

Altman is a member of Qualcomm's executive committee, providing direction and guidance on key initiatives across all areas of the business, as well as on overall vision and strategy. He began his career with the San Diego law firm of Gray, Cary, Ames & Frye (now DLA Piper), where he specialized in intellectual property, mergers and acquisitions, securities and general corporate matters. Altman joined Qualcomm in 1989 as corporate counsel with responsibility for licensing and contracts. He quickly moved up through the management ranks and became vice president and general counsel in 1992. Altman was appointed general manager of Qualcomm Technology Licensing (QTL) when that organization was formed in 1995, and in 1998 he was named executive vice president of Qualcomm and president of QTL. In 2005, he was appointed and served as president of Qualcomm until 2011, when he was appointed vice chairman.

Altman and his wife Lisa are passionate supporters of diabetes research, actively providing leadership and financial support to organizations such as JDRF and University of California, San Diego (UCSD).  Their interest in diabetes, especially type I diabetes, is personal.  Two of their children suffer from the disease as does Altman's father, brother and niece. As an example of their dedication to finding a cure, the Altmans recently pledged $10 million to the planned Clinical and Translational Research Institute (CTRI) building to be constructed on the UCSD medical campus.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing